Pheton Holdings Ltd Completes Its Initial Public Offering
Pheton Holdings Ltd, a leading provider of healthcare solutions, has successfully closed its initial public offering (IPO), marking a major achievement for the company. This IPO involved the sale of 2,250,000 Class A ordinary shares at a price of $4.00 each, generating total gross proceeds of $9 million before accounting for underwriting discounts and related expenses.
Details of the IPO
The underwriters were given the option to acquire an additional 337,500 Class A ordinary shares within a 45-day period after the closing, allowing them to address any over-allotments if needed. Following the IPO, Pheton's Class A ordinary shares are now trading on the Nasdaq Capital Market under the ticker symbol "PTHL." This is a significant step forward, as trading commenced just days prior to the official announcement.
How the Proceeds Will Be Used
The funds generated from the offering are designated for several strategic initiatives aimed at strengthening the company's capabilities and expanding its market presence. These initiatives include investments in research and development, technology enhancements, market expansion efforts, and improvements to internal controls and operational systems. Additionally, the company plans to enhance its liquidity to effectively tackle future opportunities and challenges.
Underwriters and Legal Counsel Involved
CATHAY SECURITIES, INC. played a vital role as the lead underwriter, with Dominari Securities LLC acting as a co-underwriter for the offering. The legal aspects were expertly managed by Hunter Taubman Fischer & Li LLC, who provided counsel to the company, while The Crone Law Group P.C. served as legal counsel for the underwriters.
About Pheton Holdings Ltd
Since its establishment in 1998, Pheton Holdings Ltd has been committed to advancing healthcare solutions. Through its wholly owned subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd., the company focuses on treatment planning systems for brachytherapy, a crucial targeted radiation therapy used in cancer treatment. Its flagship product, the Treatment Planning System, is designed to enhance the safety and effectiveness of brachytherapy, which delivers radioactive sources directly to patients to eradicate cancer cells and reduce tumors.
Dedication to Innovation
The company is dedicated to setting new standards of care across a variety of malignant tumor applications. Through continuous innovation and a commitment to its technology, Pheton Holdings aims to improve patient outcomes and enhance the overall effectiveness of cancer treatments.
Contact Information
For any investor inquiries or media relations, Pheton Holdings Ltd invites interested individuals to reach out via email or phone. Investors can contact the Investor Relations team at ir@ftzy.com.cn. Additionally, Jackson Lin from Lambert Global is available for inquiries at +1 (646) 717-4593 or via email at jlin@lambert.com.
Frequently Asked Questions
What is Pheton Holdings Ltd known for?
Pheton Holdings Ltd is known for its healthcare solutions, particularly in developing treatment planning systems for brachytherapy, a targeted cancer treatment.
What was the total amount raised in the IPO?
The company raised a total of $9 million in its IPO by offering 2,250,000 Class A ordinary shares.
What ticker symbol does Pheton Holdings trade under?
Pheton Holdings trades under the ticker symbol "PTHL" on the Nasdaq Capital Market.
Who were the underwriters of the IPO?
CATHAY SECURITIES, INC. served as the primary underwriter, with Dominari Securities LLC acting as a co-underwriter.
What are the future plans for the funds raised?
The proceeds from the IPO are intended for research and development, technology upgrades, market expansion, and improving operational systems.
